Federal funding changes disrupted pediatric brain cancer trials, delaying research into new treatments for deadly diseases like DIPG.

One experimental mRNA treatment for DIPG was pushed back by at least a year after a key clinical trial network lost funding.

For 8-year-old John Paul Macri, who is now in hospice, the delay may have cost him time he could not afford to lose.

Read the full story: http://cnb.cx/473klN3